Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

Rhea-AI Summary

Tempest Therapeutics, Inc. (Nasdaq: TPST) to participate in fireside chat at 35th Annual Piper Sandler Healthcare Conference. The company is a clinical-stage oncology company focusing on first-in-class therapeutics combining targeted and immune-mediated mechanisms. Management will be part of the discussion on November 28, 2023, at 3:00 p.m. ET. The live or archived recording can be accessed on the Tempest website.

BRISBANE, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classⁱ therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will participate in a fireside chat at the 35^th Annual Piper Sandler Healthcare Conference on Tuesday, November 28, 2023 at 3:00 p.m. ET.

To access the live or archived recording of the discussion, please visit the investor section of the Tempest website at https://ir.tempesttx.com.

About Tempest Therapeutics

Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company has a diverse portfolio of novel programs ranging from early research to investigation in a randomized global study in first-line cancer patients. The company’s two clinical programs, TPST-1120 and TPST-1495, target PPARα and EP2/EP4, respectively, and are advancing through trials designed to study the agents as monotherapies and in combination with approved agents. Tempest is also developing an orally available inhibitor of TREX1, a target that controls activation of the cGAS/STING pathway. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at www.tempesttx.com.

Investor & Media Contacts

Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com 

Aljanae Reynolds
Wheelhouse Life Science Advisors 
areynolds@wheelhouselsa.com

^{__________________________________
i} If approved by the FDA

FAQ

What is Tempest Therapeutics, Inc. participating in?

Tempest Therapeutics, Inc. is participating in a fireside chat at the 35th Annual Piper Sandler Healthcare Conference.

What is the focus of Tempest Therapeutics, Inc.?

The company focuses on developing first-in-class therapeutics that combine targeted and immune-mediated mechanisms in the field of oncology.

Where can the live or archived recording of the discussion be accessed?

The live or archived recording can be accessed on the investor section of the Tempest website at https://ir.tempesttx.com.